Atlas Trials

A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients

Clinical trial NCT05139719 · RECRUITING

Trial details

NCT number
NCT05139719
Sponsor
Sunshine Lake Pharma Co., Ltd.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
Start date
2023-02-15
Primary completion
2026-12-01
Enrollment
110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.